242 related articles for article (PubMed ID: 37127558)
1. Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.
Haruma K; Kinoshita Y; Yao T; Kushima R; Akiyama J; Aoyama N; Kanoo T; Miyata K; Kusumoto N; Uemura N
BMC Gastroenterol; 2023 May; 23(1):139. PubMed ID: 37127558
[TBL] [Abstract][Full Text] [Related]
2. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
3. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
4. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
5. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials.
Miwa H; Uedo N; Watari J; Mori Y; Sakurai Y; Takanami Y; Nishimura A; Tatsumi T; Sakaki N
Aliment Pharmacol Ther; 2017 Jan; 45(2):240-252. PubMed ID: 27891632
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Kawai T; Oda K; Funao N; Nishimura A; Matsumoto Y; Mizokami Y; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1033-1041. PubMed ID: 29196436
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.
Uemura N; Kinoshita Y; Haruma K; Yao T; Kushima R; Kanoo T
Clin Exp Gastroenterol; 2018; 11():51-56. PubMed ID: 29416369
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.
Mizokami Y; Oda K; Funao N; Nishimura A; Soen S; Kawai T; Ashida K; Sugano K
Gut; 2018 Jun; 67(6):1042-1051. PubMed ID: 28988197
[TBL] [Abstract][Full Text] [Related]
12. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Croxtall JD; Scott LJ
Drugs; 2010 Aug; 70(12):1593-601. PubMed ID: 20687622
[TBL] [Abstract][Full Text] [Related]
13. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.
Ashida K; Sakurai Y; Nishimura A; Kudou K; Hiramatsu N; Umegaki E; Iwakiri K; Chiba T
Aliment Pharmacol Ther; 2015 Sep; 42(6):685-95. PubMed ID: 26201312
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
Chen S; Liu D; Chen H; Liao A; Li F; Liu C; Li X; Li S; Zhang Y; Wang Y; Xia M; Guo Q; Miao X; Wen Z; Xu M; Yin H; Chen H; Chen M; Xiao Y
Aliment Pharmacol Ther; 2022 Jun; 55(12):1524-1533. PubMed ID: 35505467
[TBL] [Abstract][Full Text] [Related]
15. Lansoprazole for maintenance of remission of erosive oesophagitis.
Freston JW; Jackson RL; Huang B; Ballard ED
Drugs; 2002; 62(8):1173-84. PubMed ID: 12010078
[TBL] [Abstract][Full Text] [Related]
16. Vonoprazan versus lansoprazole in erosive esophagitis - A systematic review and meta-analysis of randomized controlled trials.
Chandan S; Deliwala S; Mohan BP; Ramai D; Dhindsa B; Bapaye J; Kassab LL; Chandan OC; Facciorusso A; Adler DG
Indian J Gastroenterol; 2023 Aug; 42(4):475-484. PubMed ID: 37418052
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
[TBL] [Abstract][Full Text] [Related]
18. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
[TBL] [Abstract][Full Text] [Related]
19. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Sharma P; Johnson DA; Monyak JT; Illueca M
Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
[TBL] [Abstract][Full Text] [Related]
20. Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis.
Vakil N
Aliment Pharmacol Ther; 2003 Feb; 17 Suppl 1():21-3. PubMed ID: 12614303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
